The solute carrier family 34 member 2 (SLC34A2) gene encodes a sodium-dependent phosphate transporter protein primarily expressed in lung, small intestine, kidney, and glandular tissues. It plays a critical role in phosphate homeostasis by mediating cellular uptake of inorganic phosphate. SLC34A2 is clinically significant due to its association with diseases such as pulmonary alveolar microlithiasis (PAM), a rare lung disorder caused by bi-allelic mutations, and its dysregulation in cancers like lung adenocarcinoma, where it may serve as a tumor-associated antigen.
SLC34A2 antibodies are immunological tools designed to detect and quantify the SLC34A2 protein in research and diagnostic contexts. These antibodies are widely used in techniques such as immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to study protein expression patterns, tissue localization, and pathological alterations. In cancer research, SLC34A2 antibodies help investigate its role in tumor progression, metastasis, and potential as a therapeutic target. Clinically, they aid in diagnosing SLC34A2-related disorders or identifying cancer biomarkers in tissue samples.
Validation of SLC34A2 antibodies is crucial, as cross-reactivity with other solute carriers or isoforms may occur. Reliable antibodies contribute to understanding SLC34A2's dual role in phosphate metabolism and disease pathogenesis, bridging basic research and clinical applications.